In Vitro Comparison of Two Most Promising H-Oximes (HI-6 and HLö-7) and Currently Commercially Available Reactivators Pralidoxime and Obidoxime in Reactivation of Cyclosarin-Inhibited Human Cholinesterases

Kamil Kuca; Jiri Cabal; Daniel Jun; Vit Koleckar

doi:10.1080/15376510701380323

In Vitro Comparison of Two Most Promising H-Oximes (HI-6 and HLö-7) and Currently Commercially Available Reactivators Pralidoxime and Obidoxime in Reactivation of Cyclosarin-Inhibited Human Cholinesterases

Toxicol Mech Methods. 2008;18(4):329-33. doi: 10.1080/15376510701380323.

Authors

Kamil Kuca¹, Jiri Cabal, Daniel Jun, Vit Koleckar

Affiliation

¹ Center of Advanced Studies, Faculty of Military Health Sciences, University of Defence Trebesska 1575, 500 01 Hradec KraloveCzech Republic.

PMID: 20020898
DOI: 10.1080/15376510701380323

Abstract

ABSTRACT This study describes the evaluation of the in vitro ability of two acetylcholinesterase (EC 3.1.1.7) reactivators, HI-6 and HLö-7, very promising at present, to reactivate human brain cholinesterases inhibited by the nerve agent cyclosarin. The results obtained (percentage of reactivation and appropriate constants characterizing the whole reactivation process) were compared with two currently available reactivators on the market: pralidoxime and obidoxime. It is clear that both promising oximes surpassed the potency of standard reactivators, especially at human relevant concentrations (10(-4) M and lower). Because of the prohibition of such experiments on humans, data obtained in this study could be used as input data for prediction of in vivo action of these drugs in future.